Evidence map›Paper›PMID 41219639›Full record

ReviewHuman cell2025

The "dual personality" of LOXL3: a tumor accomplice and a new hope for immunotherapy.

Shuang Wu, Chao Huang

Abstract readReview
PubMed Publisher
In one paragraph

Review in Human cell, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Shuang WuMedical School, Kunming University of Science and Technology, Kunming, 650500, China.
Chao HuangMedical School, Kunming University of Science and Technology, Kunming, 650500, China. c_huang@kust.edu.cn.ORCID http://orcid.org/0000-0002-4913-921X

Funding

Innovative Research Group Project of the National Natural Science Foundation of China 82260461Innovative Research Group Project of the National Natural Science Foundation of China 82560487Yunnan Fundamental Research Projects 202101BE070001-004
6 · The paper itself

Abstract

The lysyl oxidase family is a group of copper-containing amine oxidases involved in the remodeling of the extracellular matrix, and regulates cell signaling, metabolism, organ development, and immunity by modifying the cellular matrix. Among them, LOXL3 had been shown to regulate the proliferation, migration, and invasion of breast, colorectal, lung, melanoma, and gastric cancers. Differential expression of LOXL3 in tumor affects tumor progression by modulating immune microenvironment, where LOXL3 plays a role in regulating immune cell infiltration, immune checkpoints, and the establishment of tumor drug resistance. Here, we summarize the structure, mechanism, and functional role of LOXL3 in tumor and tumor immune microenvironment. Further, we explored strategies to improve the immunotherapy efficacy by targeting LOXL3 in tumor. Based on its properties in immunity, we explored strategies to improve the immune efficacy of LOXL3 in immunotherapy.

Indexed as

Amino Acid OxidoreductasesImmunotherapyNeoplasmsAnimalsCell MovementCell ProliferationDrug Resistance, NeoplasmExtracellular MatrixHumansNeoplasm InvasivenessTumor MicroenvironmentAmino Acid OxidoreductasesLOXL3 protein, humanImmune infiltrationImmune microenvironmentLOXL3Tumor

Identifiers

PMID41219639

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.